IDO blockade negatively regulates the CTLA-4 signaling in breast cancer cells
Author:
Publisher
Springer Science and Business Media LLC
Subject
Immunology
Link
https://link.springer.com/content/pdf/10.1007/s12026-023-09378-0.pdf
Reference37 articles.
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.
2. Liu L, Wang Y, Miao L, Liu Q, Musetti S, Li J, et al. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. Mol Ther. 2018;26(1):45–55. https://doi.org/10.1016/j.ymthe.2017.10.020.
3. Azimnasab-Sorkhabi P, Soltani-Asl M, Kfoury Jr JR, Algenstaedt P, Mehmetzade HF, Hashemi Aghdam Y. The impact of leptin and its receptor polymorphisms on type 1 diabetes in a population of northwest Iran. Ann Hum Biol. 2022;49(7–8):317–22. https://doi.org/10.1080/03014460.2022.2134453.
4. Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017;83:258–65. https://doi.org/10.1016/j.ejca.2017.06.023.
5. Soltani Asl M, Azimnasab-Sorkhabi P, Abolfathi AA, Hashemi AY. Identification of nucleotide polymorphism within the NeuroD1 candidate gene and its association with type 1 diabetes susceptibility in Iranian people by polymerase chain reaction-restriction fragment length polymorphism. J Pediatr Endocrinol Metab. 2020;33(10):1293–7. https://doi.org/10.1515/jpem-2019-0441.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advancing drug-response prediction using multi-modal and -omics machine learning integration (MOMLIN): a case study on breast cancer clinical data;Briefings in Bioinformatics;2024-05-23
2. Landscape of unconventional γδ T cell subsets in cancer;Molecular Biology Reports;2024-01-30
3. Conventional T Cell Subsets and Their Roles Within the Tumor Microenvironment;Interdisciplinary Cancer Research;2024
4. The combination of IDO and AHR blockers reduces the migration and clonogenicity of breast cancer cells;Immunologic Research;2023-12-28
5. Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer;Frontiers in Oncology;2023-10-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3